# VAXDIGM

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/vaxdigm

- Industry: Biotechnology
- Headquarters: Seoul, South Korea
- Website: www.vaxdigm.com/
- Total disclosed funding: $2M
- Latest round: Series A (Oct 23, 2024)
- Investors on record: 7

## About

Based in Seoul, South Korea, and founded in 2021 by Seung-Hoo Kim, VAXDIGM operates as a biotechnology company that is focused on the research and development of vaccines. In May 2026, VAXDIGM raised KRW 1.5 billion in venture funding from new investor Ministry of SMEs and Startups, with participation from returning investor Korea Tech Incubator for Startup, being selected for Accelerator Investment-Driven Tech Incubator Program Deep-Tech TIPS. As of July, 2026, Kim Seong-jae is the CEO of the company. 

VAXDIGM uses the original technology for rapid vaccine production to develop improved vaccines and future vaccines, including twin-demic (COVID-19 & flu) vaccines. The firm offers cost-effective growth of artificial antigen vaccines using source technology for development and production using microorganisms rather than moth and animal cells.

The company plans to use the July 2026 funding to validate and commercialize its protein production platform.

## Funding rounds

- Series A, Oct 23, 2024, $2M — New Paradigm Investment, Infobank, The Invention Lab, Chung-Ang University KAIC, FIND US, LITALCO Inc.
- Seed, Jun 1, 2022 — Korea Tech Incubator for Startup, New Paradigm Investment
- Seed, May 9, 2022 — New Paradigm Investment

## Investors

- New Paradigm Investment (https://capitalatlas.ai/funds/new-paradigm-investment) — Seed, Series A
- Korea Tech Incubator for Startup — Seed
- Infobank (https://capitalatlas.ai/funds/infobank) — Series A
- The Invention Lab (https://capitalatlas.ai/funds/the-invention-lab) — Series A
- Chung-Ang University KAIC — Series A
- FIND US — Series A
- LITALCO Inc. — Series A